H ypertension is one of the most important determinants of micro-and macrovascular complications in patients with diabetes. Recent guidelines on treating hypertension in diabetes patients, based on clinical evidence of protection against target organ damage, especially as demonstrated by renal outcomes, recommended that office blood pressure (BP) be lowered to 130/ 80 mmHg in these patients. 1 However, very few studies have consistently achieved BP levels as low as 130/80 mmHg in diabetic patients.A landmark report related to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study showed that targeting a systolic BP of o120 mm Hg, as compared with o140 mm Hg, did not reduce the rate of a composite outcome of fatal and non-fatal major cardiovascular events in type 2 diabetics with at high risk for cardiovascular events. 2 As a secondary outcome, intensive BP lowering was effective in reducing total stroke (P¼0.01) and non-fatal stroke events (P¼0.03). 2 Although many observational studies support the 'the lower, the better' theory, it has not been clearly shown that the aggressive lowering of BP is indeed beneficial in the management of hypertension. The ACCORD study was a randomized control study that examined cardiovascular disease as an outcome. The extent of BP lowering in diabetes should be individualized by cardiovascular complications, microvascular complications and the severity of diabetes and hypertension. In the ACCORD subjects, 34% had experienced previous cardiovascular events, and 87% were on antihypertensive medications. The mean baseline BP was as low as 139/76 mmHg in all patients. It is not surprising that no benefit of a further reduction of BP was seen when targeting a systolic BP of o120 mm Hg. In the early stage of diabetes, aggressive control of risk factors could be effective for reducing cardiovascular outcomes. 3,4 In clinical practice, physicians occasionally hesitate to add antihypertensive medications to achieve clinic BP of 130/80 mmHg. The target BP level in patients with diabetes remains to be established. In terms of individualized BP control, ambulatory BP monitoring (ABPM) is the most useful tool for accurately evaluating BP level and variability.For the assessment and management of BP, ABPM is better than clinic BP. 5 ABPM can more reliably and easily assess actual BP levels than clinic BP and is helpful for predicting cardiovascular events, target organ damage and antihypertensive effects. Even in diabetes, we have shown that ambulatory BP levels more accurately predict future cardiovascular events. 5 An abnormal dipping pattern has been established as a risk factor, 6 and white-coat hypertension and masked hypertension have been shown to be moderate risk factors. 7,8 We showed that BP variability during sleep was a risk factor for cardiovascular disease even after adjusting for BP levels in patients with diabetes. 9 Unless ABPM is performed, it is difficult to assess these measures and to perform detailed assessments, especially of nighttime BP. In the meantime, ...